Direct Impact

Concepts for which Peter Wark has direct influence:

severe asthma
mepolizumab omalizumab
cystic fibrosis
frequent exacerbations
gastrointestinal microbiome
allergic eosinophilic
eosinophil level

External impact

Concepts related to the work of other authors for which Peter Wark has influence:

pregnant women
critical coronavirus
prone positioning
hospitalized pregnancies
cardiomyopathy maternal
symptom onset
acute respiratory distress syndrome

Prominent publications by Peter Wark

KOL-Index: 52 To date, 18 living recommendations for the clinical care of pregnant and postpartum women with COVID-19 have been issued by the National COVID-19 Clinical Evidence Taskforce. This includes recommendations on mode of birth, delayed umbilical cord clamping, skin-to-skin contact, breastfeeding, rooming-in, antenatal corticosteroids, angiotensin-converting enzyme inhibitors, disease-modifying ...
Known for
Recommendations Covid‐19 | Women Covid-19 | Postpartum | Taskforce Living
KOL-Index: 5 BACKGROUND: Clinicians are increasingly recognizing severe asthma patients in whom biologics and other add-on therapies lead to dramatic improvement. Currently, there is no agreed-upon super-responder (SR) definition. OBJECTIVE: To survey severe asthma experts using a modified Delphi process, to develop an international consensus-based definition of a severe asthma SR. METHODS: The Delphi ...
Known for
24 | Well-Controlled Asthma | Members | Rejection
KOL-Index: 2 Hypothesis: We propose in patients with the dual phenotypes of severe allergic and eosinophilic asthma, that Mepolizumab is as effective as Omalizumab. However, we will also go on and identify key clinical biomarkers that will clarify which patients will respond best to each of these interventions. This study will be the first direct clinical comparison of these agents and will apply expert ...
Known for
Key Cli | Reduced Effectiveness | Asthma Questionnaire | Edge Biotechnology
KOL-Index: 2 This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in COPD participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 57 weeks, consisting of 2 screening visits, run-in ...
Known for
Participant Participation | Maximum Duration | Copd Partici
KOL-Index: 2 BACKGROUND: Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe and efficacious in people with cystic fibrosis aged 12 years or older with at least one F508del-CFTR allele. We aimed to assess the magnitude and durability of the clinical effects of this triple combination ...
Known for
Orally Elexacaftor | Cystic | 12 | Ivacaftor Run-In Period
KOL-Index: 2 Chronic obstructive pulmonary disease (COPD) affects approximately 7.5% of the Australian population over 40 years of age. Many people with COPD suffer periodic exacerbations that can make them feel much worse. We have effective treatments for managing the symptoms of COPD, but they do not cure the disease. The “microbiome” is the term given to all the microorganisms, such as bacteria, that ...
Known for
Protective Roles | Pathogenic Microbes
KOL-Index: 2 Mepolizumab is an anti-interleukin-5 ( IL-5) monoclonal antibody that neutralizes IL-5 and reduces eosinophil counts in both sputum and blood. Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody (mAb) used in the treatment of severe allergic eosinophilic asthmaThe investigators propose that in patients with the dual phenotypes of severe allergic and eosinophilic asthma, that ...
Known for
Eosinophil Counts
KOL-Index: 2 Aim To determine the safety and efficacy of LUM/IVA in subjects >12 years of age with CF, homozygous for F508del mutation of CFTR and an FEV1<40% of predicted normal, by comparing those patients treated with LUM/IVA with a cohort of age and sex matched CF controls with another set of mutations that lead to severe CFTR dysfunction (belonging to Class I, II or III), with an FEV1<40%5. . Aim To ...

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172